A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
Completed · Phase 3 · NCT05214768
Conditions: Eosinophilic Gastroenteritis
At a glance
- Research payments reported, 2025
- $10,270
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 48
About the trial
- Sponsor
- Celgene
- Tested
- CC-93538 (drug), Placebo (drug)
- Dates
- Started 2022-03-04; completion 2025-08-22
- Results posted
- Yes
The purpose of this study is to evaluate the safety and efficacy of CC-93538 in adult and adolescent participants with eosinophilic gastroenteritis.
From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $10,270 in research payments for this study in 2025 (3 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $10,270
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.